Susan L. Serbin’s Talkin‘ ’Bout My Generation appears every other week.

Alongside our long-standing obsession with artisanally crafted cuisine rests a similar fixation on elevated cocktails crafted ...

Quarterly Revenue: Increased 75.4% year-over-year to $255.7 million. Genomics Revenue: $193.8 million, representing 89% year-over-year growth. Oncology Testing Growth: 31% year-over-year with approxim ...

CHICAGO, May 05, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of ...

When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like they're standing on a dock watching the stock sail off to the horizon.It's understandable if you identify with this. After ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of Notetaker, an AI-powered clinical ...

The Chicago-based startup formed in 2020 by Tempus AI executives Ryan Fukushima and Eric Lefkofsky is using an artificial intelligence platform, PathOS, to develop drugs, primarily in the oncology ...